PPAR γ agonist, pioglitazone, suppresses melanoma cancer in mice by inhibiting TLR4 signaling.
CONCLUSIONS: The results indicate that pioglitazone, a PPARγ agonist, has a beneficial protective effect against melanoma via interfering with the TLR4-dependent signaling pathways.
PMID: 31509504 [PubMed - in process]
Source: Journal of Pharmacy and Pharmaceutical Sciences - Category: Drugs & Pharmacology Tags: J Pharm Pharm Sci Source Type: research
More News: Actos | Cancer | Cancer & Oncology | Drugs & Pharmacology | Genetics | Melanoma | Skin Cancer | Study